Igc pharma: fiscal year 2025 financial and operational highlights - a year of transformative progress in alzheimer's innovation

Potomac, maryland / access newswire / june 30, 2025 / igc pharma, inc. (nyse american:igc) ("igc" or the "company"), a clinical-stage biotechnology company leveraging ai to develop innovative treatments for alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined fiscal year 2025, ended march 31, 2025. this past year has been nothing short of transformative, marked by significant clinical progress, strategic expansion, and growing recognition for our pioneering approach to alzheimer's disease.
IGC Ratings Summary
IGC Quant Ranking